We are pleased to announce that our team has published a landmark study describing the first pyrrolobenzodiazepine (PBD)-based proteolysis-targeting chimera (PROTAC), opening a new therapeutic avenue for cancers driven by…
First PBD-PROTAC Reported
We are pleased to announce that our team has published a landmark study describing the first pyrrolobenzodiazepine (PBD)-based proteolysis-targeting chimera (PROTAC), opening a new therapeutic avenue for cancers driven by…